The NCPE recommends that cabozantinib (Cabometyx®) for the treatment of advanced or metastatic clear-cell RCC not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical
The NCPE recommends for the infantile presentation, that sebelipase alfa (Kanuma®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. For the paediatric adult presentation, sebelipase alfa has not demonstrated robust evidence of additional clinical benefit and recommends that sebelipase alfa not be considered
The NCPE recommends that pembrolizumab (Keytruda) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.